Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian Indices Trade Higher; Nestle & Reliance Industries Top Gainers
Wed, 19 Feb 12:30 pm

Share markets in India are presently trading on a strong note. Benchmark indices staged a gap-up opening today after falling over the past four sessions as higher Asian markets lifted the sentiment.

Sectoral indices are trading mixed with stocks in the energy sector and telecom sector witnessing buying interest, while auto stocks are witnessing selling pressure.

The BSE Sensex is trading up by 281 points while the NSE Nifty is trading up by 87 points.

The BSE Mid Cap index and the BSE Small Cap index are trading up by 0.9% and 1.1%, respectively.

The rupee is trading at 71.54 against the US$.

Speaking of Indian share markets, we've been telling you about the rebound in smallcap stocks in 2020 for quite some time now.

And the market trend since the start of 2020 tells us, it's already happening!

Have a look at the chart below:

Smallcaps Are Way Ahead of the Sensex in 2020


As you can see, since the start of 2020, smallcaps have beaten largecaps by a wide margin.

But this is just the start.

We believe smallcaps have a long way to go.

You can make good gains with a careful selection of smallcap stocks and long-term horizon.

As per Richa Agarwal, editor of our premium smallcap service Hidden Treasurefundamentally strong smallcap stocks will not only survive but thrive in the long term.

In news from the aviation space, Jet Airways' Committee of Creditors (CoC) on Tuesday decided to extend the deadline for submission of bids to March 10 as a new entity evinced interest in the airline.

The deadline for submitting the bids for Jet Airways, which is undergoing insolvency process, ended on Monday.

Against this backdrop, the CoC extended the deadline for submission of bids to March 10.

Earlier, South American conglomerate Synergy Group and New Delhi-based Prudent ARC were given time to submit resolution plan. Reportedly, they failed to meet the deadline.

The beleaguered airline had shut its operations in April last year due to severe cash crunch.

Jet Airways was admitted under the insolvency process on June 20, 2019, after its bankers failed to find any takers despite months of negotiations.

The airline stopped flying on April 17 and it had around 14,000 employees on that date.

How all this pans out remains to be seen. Meanwhile, we will keep you updated on the latest developments from this space.

Moving on to news from the pharma sector, shares of Aurobindo Pharma surged 19% today after the company's Unit IV received Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from the US health regulator.

In a BSE filing, Aurobindo Pharma said that the USFDA had inspected company's Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad, from 4th to 13th November 2019.

At the end of the inspection, the company had issued a 'Form 483' with 14 observations.

On November 13, 2019, the company had informed the stock exchanges that none of these observations are related to data integrity issues.

Currently, Unit 4 has 15 abbreviated new drug applications (ANDA) approvals pending over next one year.

Earlier this month, the company had reported a strong growth of 11.9% in operational revenues at Rs 59 billion in the December quarter (Q3FY20).

The company's consolidated earnings before interest, tax, depreciation, and amortisation (EBITDA) margin remained stable at 20.5% in Q3FY20. EBITDA grew 11.2% YoY at Rs 12.1 billion.

However, profit after tax (PAT) declined 1% YoY to Rs 7.1 billion, due to higher depreciation.

Aurobindo Pharma share price is presently trading up by 17%.

To know more about the company, you can read Aurobindo Pharma's latest result analysis on our website.

Speaking of pharma sector, in the video below, Tanushree tells us where the sector stands now and also about the potential for a rebound.

Watch Now...

Meanwhile, Tanushree is counting on 7 top stocks from the Indian stock market that will benefit from what she calls the Rebirth of India.

As per her, now is the right time to buy these stocks to profit from the Rebirth of IndiaYou can read about them here.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian Indices Trade Higher; Nestle & Reliance Industries Top Gainers". Click here!